Welcome to Printing Life
CellDrive 3D, S.L. was established in December 2020 as a start-up recognized as a Knowledge-Based Company. The Science Equity fund, BeAble Capital, and the University of Valladolid (Spain), through its research group Bioforge, a multidisciplinary group focused on advanced systems for a medical and bioengineering applications, are part of the founding group. CellDrive 3D's main research interest lies in the development of personalized, intelligent, biofunctional protein polymers for advanced biomedical devices.
Our majority partner, BeAble Capital SGEIC SA, is a venture firm specializing in Science Equity, focused on technology transfer in Deep Science. Through its fund, BeAble Innvierte Kets Fund, FCR, it invests in seed and early-stage disruptive technologies that possess strong intellectual property and competitive adventages. The firm targets high-growth markets by addressing unmet needs and delivering high-value solutions.
Technology
CellDrive 3D features a unique bioink platform that enables the production of living tissue on demand through genetic engineering techniques. Its animal-free formulation mimics the extracellular matrix, maximizing cell viability and enchancing 3D resolution.
Live/dead staining of 3D-printed scaffolds loaded with HaCaT (8 × 106 cells/mL) and HUVEC (2 × 107 cells/mL) cells embedded in CD3D ELR BioInk RGD, incubated over culture periods of 1, 3, 7, and 14 days to assess cell viability and proliferation. Living cells were stained with calcein AM (green fluorescence), and dead cells with ethidium homodimer (red fluorescence).
Staining of filamentous actin (F-actin) (red) and cell nuclei (blue) of 3D-printed scaffolds stained with Rhodamine phalloidin and DAPI, respectively, and loaded with HFF-1-HaCaT co-cultures (6 × 106 cells/mL) after 7 days of incubation. Volume reconstruction using 0.5 μm z-steps.
Product
CD3D ELR BioInk RGD is engineered using recombinant DNA technology to facilitate seamless 3D printing. This innovative biological material, based on human elastin sequence, offers biomimetic, biocompatible, and biodegradable properties, making it ideal for advanced biomedical applications.
Additionally, our bioink possesses the essential mechanical properties to ensure excellent printability and long-term stability of the final structure without the need for crosslinkers nor photoinitiators. It is supplied sterile and ready to use, making it an excellent choice for a wide range of 3D bioprinting applications in tissue engineering and regenerative medicine.
Furthermore, it can be used to 3D-print scaffolds embedded with cells for the development of in vitro tissue models, and to encapsulate drug-loaded nanoparticles for drug screening and drug delivery.
Our CD3D ELR BioInk RGD is available in three different concentrations: low, medium, and high. Selecting the appropiate concentration allows you to control the stiffness of the 3D-printed structures according to your specific requirements and applications.
Biomedical applications:
Drug development models
In vitro tissue models
Therapeutic tissues
Drug delivery
Contact Us
Send us an email and tell us what else you want to know about our BioInk:
info@celldrive3d.com
Or give us a call. We will be happy to assist you and discuss any question you may have about us:
+34 983 003 021
